Simulating lifetime outcomes associated with complications for people with type 1 diabetes

PharmacoEconomics

Volumn 31, Issue 6, 2013, Pages 509-518

  Lung, Tom W C ^a   Clarke, Philip M ^a   Hayes, Alison J ^b   Stevens, Richard J ^c   Farmer, Andrew ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADOLESCENT; ARTICLE; BELOW KNEE AMPUTATION; BLINDNESS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE CONTROL; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FAILURE; LIFE EXPECTANCY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; SIMULATION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SEX FACTORS;

EID: 84878884854     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0047-4     Document Type: Article

References (38)

1. American Diabetes Association. Executive summary: standards of medical care in diabetes - 2012. Diabetes care. 2012;35(Suppl 1):S4-10.
2. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet. 2004;364(9446):1699-700.
3. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of Type I diabetes - the analysis of the data on published incidence trends [erratum appears in Diabetologia. 2000;43(5):685]. Diabetologia. 1999;42(12):1395-403.
4. Group DP. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med (J Br Diabet Assoc). 2006;23(8):857-66.
5. Tomar RH, Lee S, Wu SY, Klein R, Klein BE, Moss SE, et al. Disease progression and cost of insulin dependent diabetes mellitus: development and application of a simulation model. J Soc Health Syst. 1998;5(4):24-37.
6. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5-26.
7. Clarke PM, Gray AM, Briggs A, Farmer A, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS no. 68). Diabetologia. 2004;47:1747-59.
8. Framingham Heart Study: a project of the National Heart, Lung and Blood Institute and Boston University. Framingham (MA); Framingham Heart Study; 2011. http://www.framinghamheartstudy.org/risk/index.html. Accessed Feb 2011.
9. Zgibor JC, Ruppert K, Orchard TJ, Soedamah-Muthu SS, Fuller J, Chaturvedi N, et al. Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diabet Res Clin Pract. 2010;88(3):314-21.
10. Nathan DM, Cleary PA, Backlund J-YC, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-53.
11. Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA. 2005;294(14):1782-7.
12. Miao J, Ye W, Sparen P, Apelqvist J, Nyren O, Brismar K, et al. Risks of nontraumatic lower-extremity amputations in patients with type 1 diabetes: a population-based cohort study in Sweden. Diabetes Care. 2008;31(8):1536-40.
13. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86.
14. Oke J, Stevens RJ, Perera R, Dunger D, Dalton N, Neil A, et al. Current and alternative programmes for monitoring renal function in type 1 diabetes: modelling study based on the Oxford regional prospective study. Prim Health Care Res Dev. 2010;11(Suppl 1):43.
15. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care. 1999;22(1):99-111.
16. Dagra: digitize graphical data. Version 2.0.11. Hamilton: Blue Leaf Software; 2012. http://www.blueleafsoftware.com/Products/Dagra/. Accessed 11 May 2012.
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
18. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, FIELD Study Investigators, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [errata appear in Lancet. 2006 Oct 21;368(9545):1415 and 2006;368(9545):1420]. Lancet. 2005;366(9500):1849-61.
19. Hayes AJ, Leal J, Kelman CW, Clarke PM. Risk equations to predict life expectancy of people with type 2 diabetes mellitus following major complications: a study from Western Australia. Diabet Med. 2011;28(4):428-35.
20. Kelly PK, Clarke PM, Hayes AJ, Gerdtham UG, Nilsson PM, Eliasson B, et al. Predicting the mortality of people with type 2 diabetes mellitus following a major complication: a study using Swedish Nation Diabetes Register data. Diabetologia. 2011;54(Suppl 1):S1-542.
21. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease [erratum appears in Circulation. 2002 May 7;105(18):2230]. Circulation. 2002;105(11):1354-9.
22. Icks A, Trautner C, Haastert B, Berger M, Giani G. Blindness due to diabetes: population-based age- and sex-specific incidence rates. Diabet Med. 1997;14(7):571-5.
23. Centers for Disease Control and Prevention, National Center for Health Statistics. Vital statistics of the United States, 1991: life tables. Vol. II, Sect. 6. Hyattsville (MD): Centers for Disease Control and Prevention, National Center for Health Statistics; 1995. http://www.cdc.gov/nchs/data/lifetables/ life91-2acc.pdf. Accessed 14 Aug 2011.
24. Hougaard P. Analysis of multivariate survival data (statistics for biology and health). Berlin: Springer; 2000.
25. Lung TW, Hayes AJ, Hayen A, Farmer A, Clarke PM. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res. 2011;20(10):1669-78.
26. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia. 2006;49(4):660-6.
27. United Kingdom, interim life tables, 1980-82 to 2007-09. Newport; Office of National Statistics; 2010. http://www.ons.gov.uk/ons/publications/re- reference-tables.html?edition=tcm%3A77-61850. Accessed 3 Aug 2011.
28. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications - the Pittsburgh epidemiology of diabetes complications study experience. Diabetes. 2006;55(5):1463-9.
29. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the UK. Diabet Care. 2006;29(4):798-804.
30. Narayan KMV. Glycemic control and cardiovascular disease in patients with type 1 diabetes. Clin Diabet. 2006;24(2):88.
31. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabet Care. 2007;30(6):1638-46.
32. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48:868-77.
33. Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson A-M, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140-6.
34. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjornsdottir S, Swedish Natl Diabet R. A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med. 2011;28(10):1213-20.
35. Gerdtham UG, Clarke P, Hayes A, Gudbjornsdottir S. Estimating the cost of complications of diabetes from inpatient admissions in Sweden using administrative hospitalization data. Pharmacoeconomics. 2009;7(1):81-90.
36. Clarke PLJ, Kelman C, Smith M, Colagiuri S. Estimating the cost of complications of diabetes in Australia using administrative health care data. Value Health. 2008;11(2):199-206.
37. Chan JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K-H, et al. Diabetes in Asia epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129-40.
38. Panel ADAC. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27:2262-5.